Buffered Intrathecal Electrolyte Dextrose Injection Sales

Buffered Intrathecal Electrolyte Dextrose Injection Sales Market Outlook

The global buffered intrathecal electrolyte dextrose injection market is projected to reach approximately USD 1.2 billion by 2035, growing at a CAGR of around 6.5% during the forecast period from 2025 to 2035. This growth is driven by the rising prevalence of chronic pain conditions, increasing demand for advanced pain management therapies, and the expanding applications of buffered intrathecal injections in various medical fields such as neurology, oncology, and anesthesia. Furthermore, the growing geriatric population with age-related ailments and the increasing number of surgical procedures that require effective pain management are significant factors propelling the market forward. Innovative formulations and improvements in injection techniques are also expected to enhance the product offerings, contributing to market expansion.

Growth Factor of the Market

The growth of the buffered intrathecal electrolyte dextrose injection market can be attributed to several factors, including the increasing incidence of neurological disorders, which require precise and effective treatment options. The rise in the geriatric population, who are more susceptible to conditions such as chronic pain and neurological diseases, is another crucial driver. Additionally, advancements in medical technologies and improved healthcare infrastructures across regions facilitate better access to specialized treatments, thereby enhancing the usage of intrathecal injections. Furthermore, the increasing acceptance and adoption of minimally invasive procedures in pain management have created a favorable environment for the growth of this market segment. The enhancement of patient care due to evolving treatment methodologies also adds to the market's positive outlook.

Key Highlights of the Market

• The market is projected to achieve significant growth, with a CAGR of 6.5% from 2025 to 2035.
• North America holds a substantial share of the market, driven by advanced healthcare facilities and high adoption rates of innovative therapies.
• Chronic pain management continues to be a primary application area, contributing significantly to market revenue.
• Technological advancements in drug delivery systems are expected to propel market growth further.
• The increasing focus on research and development to create more effective formulations is a notable trend in the market.

By Product Type

Sodium Chloride Solution:

Sodium Chloride Solution is one of the primary product types in the buffered intrathecal electrolyte dextrose injection market. It is commonly used as a diluent for various injectable medications and plays a critical role in maintaining electrolyte balance during intrathecal procedures. This solution is favored for its isotonic properties, ensuring that it does not disrupt the osmotic balance within the cerebrospinal fluid, making it ideal for pain management and treatment of various medical conditions. Its widespread acceptance among healthcare professionals further strengthens its market presence and contributes to its growth prospects.

Ringer's Solution:

Ringer's Solution is another important product type in the buffered intrathecal electrolyte dextrose injection market. This solution, which contains a balanced mix of electrolytes, is particularly beneficial in clinical settings where fluid and electrolyte replacement is necessary. It is extensively utilized in patients requiring careful management of their physiological states, especially during surgical procedures and in critical care settings. Its ability to more closely mimic the body's natural fluid composition makes it a preferred choice among clinicians, thus bolstering its market demand and relevance.

Normal Saline Solution:

Normal Saline Solution, a sterile solution of sodium chloride in water, is frequently used in medical settings for hydration and as an intravenous fluid. Within the buffered intrathecal electrolyte dextrose injection market, normal saline is utilized for its compatibility with various medications, enabling effective and safe dilutions. Its broad applications in various medical scenarios, such as post-operative care and emergency settings, ensure its continual demand. Additionally, its ease of availability across hospitals and clinics contributes to its sustained growth within the market.

Sterile Water:

Sterile Water serves as a versatile ingredient in the buffered intrathecal electrolyte dextrose injection market, primarily used for diluting medications before administration. Its purity and absence of contaminants make it an essential component in maintaining patient safety during intrathecal injections. The increasing emphasis on sterile environments in healthcare settings has heightened the demand for sterile water, ensuring its significance in the overall market. As healthcare facilities continue to prioritize safety and sterility, the market for sterile water is expected to flourish correspondingly.

Lactated Ringer's Solution:

Lactated Ringer's Solution is a specialized isotonic solution used in buffered intrathecal electrolyte dextrose injections. It contains a mixture of electrolytes that closely resembles human plasma, making it ideal for fluid resuscitation and electrolyte replenishment. This solution is particularly valuable in surgical and emergency departments, where rapid restoration of fluid balance is crucial. The increasing adoption of lactated Ringer's solution in clinical practices enhances its relevance in the market, especially in settings where patient care and recovery are of utmost importance.

By Application

Pain Management:

Pain management is one of the leading applications of buffered intrathecal electrolyte dextrose injections. These injections provide targeted relief for patients suffering from chronic pain conditions, including neuropathic pain and cancer-related pain. The efficacy of these injections in delivering medication directly to the central nervous system minimizes systemic side effects, making them a preferred choice among healthcare providers. As the prevalence of chronic pain continues to rise globally, the demand for effective pain management solutions, including buffered intrathecal injections, is expected to grow significantly.

Neurology:

In the field of neurology, buffered intrathecal electrolyte dextrose injections are used for a variety of therapeutic interventions, including the treatment of conditions like multiple sclerosis, severe headaches, and spinal fluid disorders. The direct delivery of neuroactive drugs via intrathecal injection allows for higher drug concentrations at the site of action, leading to improved patient outcomes. With the increasing incidence of neurological disorders worldwide, the neurology segment of the market is positioned for substantial growth as more healthcare providers recognize the benefits of this method of treatment.

Oncology:

Buffered intrathecal electrolyte dextrose injections have found significant application in oncology, where they are utilized for the management of pain associated with cancer, as well as for the delivery of chemotherapy agents directly to the central nervous system. This targeted approach allows for enhanced effectiveness while minimizing exposure to systemic side effects, which is critical for patients undergoing cancer treatment. The rising burden of cancer across the globe is expected to drive the demand for specialized treatments, including buffered intrathecal injections, thus bolstering the oncology segment of the market.

Anesthesia:

The application of buffered intrathecal electrolyte dextrose injections in anesthesia is primarily focused on providing effective analgesia during surgical procedures. The ability to administer anesthetic agents directly into the cerebrospinal fluid allows for rapid onset of action and improved pain control, which is essential in surgical settings. As the number of surgical procedures increases globally, the utilization of these injections in anesthesia is projected to grow, further enhancing the significance of this application segment within the market.

Others:

In addition to the primary applications mentioned above, buffered intrathecal electrolyte dextrose injections have various other applications in medical practice. These may include their use in the management of spinal fluid disorders, treatment of severe headaches, and other specialized pain management scenarios. As healthcare continues to evolve, the recognition of the benefits of intrathecal injections in niche applications is likely to expand, contributing to the overall growth of the buffered intrathecal electrolyte dextrose injection market.

By Distribution Channel

Hospitals:

Hospitals represent one of the primary distribution channels for buffered intrathecal electrolyte dextrose injections, as they provide comprehensive care and access to specialized treatment options. The presence of specialized departments such as pain management, neurology, and oncology within hospitals ensures that patients receive targeted therapies that include intrathecal injections. With the increasing number of patients seeking advanced pain management solutions and neurological treatments, hospitals are well-positioned to drive significant demand for these injections.

Clinics:

Clinics, particularly those specializing in pain management and neurology, play a crucial role in distributing buffered intrathecal electrolyte dextrose injections. These settings offer personalized treatment plans and patient-centered care, making them attractive options for individuals seeking relief from chronic pain and neurological conditions. The growing trend of outpatient procedures and dependency on specialized clinics for pain management is expected to bolster the uptake of these injections, positioning clinics as a vital distribution channel within the market.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) have emerged as an essential distribution channel for buffered intrathecal electrolyte dextrose injections. These centers provide cost-effective, efficient healthcare solutions for procedures requiring anesthesia and pain management. The shift towards outpatient surgery and minimally invasive techniques has facilitated the rise of ASCs, where intrathecal injections are frequently employed. As the healthcare system emphasizes patient convenience and reduced recovery times, ASCs are anticipated to witness increased adoption rates of buffered intrathecal injections.

Online Pharmacies:

Online pharmacies are becoming an increasingly relevant distribution channel for buffered intrathecal electrolyte dextrose injections, offering a convenient platform for healthcare providers and patients to access these specialized products. The growth of e-commerce in the pharmaceutical sector has enabled greater accessibility to various medication formulations, including intrathecal injections. The ability to order such specialized products online, combined with growing consumer preference for home healthcare solutions, is expected to enhance the market presence of online pharmacies in the coming years.

Others:

In addition to hospitals, clinics, ASCs, and online pharmacies, other distribution channels, such as specialty pharmacies and home healthcare providers, are also significant contributors to the buffered intrathecal electrolyte dextrose injection market. These channels typically focus on providing tailored solutions for specific patient needs, particularly for those requiring ongoing management of chronic pain and neurological disorders. As the healthcare landscape continues to evolve towards more patient-centric models, these alternative distribution channels are likely to gain further prominence.

By Ingredient Type

Sodium Chloride:

Sodium Chloride is a fundamental ingredient in buffered intrathecal electrolyte dextrose injections, primarily serving as an electrolyte to maintain proper fluid balance in the body. As a key component, it aids in ensuring isotonicity when it is mixed with dextrose and other ingredients, which is critical for safe administration. Its widespread use in various medical applications and compatibility with other medications make sodium chloride an indispensable ingredient, driving its continued demand in the market.

Dextrose:

Dextrose, a simple sugar, is another essential ingredient in buffered intrathecal electrolyte dextrose injections. It serves not only as a source of energy but also enhances the therapeutic efficacy of the injections by facilitating drug absorption. The inclusion of dextrose in these formulations is particularly beneficial for patients undergoing complex treatment regimens, as it helps maintain overall energy levels and supports recovery. The increasing recognition of the importance of energy supplementation in clinical settings ensures the sustained relevance of dextrose as a critical ingredient in the market.

Calcium Chloride:

Calcium Chloride is utilized in buffered intrathecal electrolyte dextrose injections for its electrolyte-replenishing capabilities. This ingredient plays a vital role in various physiological processes and is essential for maintaining the body's acid-base balance. Its incorporation into intrathecal formulations aids in achieving optimal therapeutic outcomes, particularly in patients with electrolyte imbalances or those undergoing extensive treatments. The growing emphasis on maintaining electrolyte levels in patients reinforces the importance of calcium chloride in this market segment.

Potassium Chloride:

Potassium Chloride is included in buffered intrathecal electrolyte dextrose injections primarily for its role in preventing hypokalemia, a condition characterized by low potassium levels in the blood. This ingredient is critical in ensuring that patients receiving intrathecal injections maintain adequate potassium levels, which is particularly pertinent in surgical and critical care settings. Given the increasing awareness of the importance of electrolyte balance in patient care, the demand for potassium chloride in these formulations is expected to grow steadily.

Magnesium Sulfate:

Magnesium Sulfate is another vital ingredient in buffered intrathecal electrolyte dextrose injections, known for its muscle-relaxing properties and role in neurological function. Its inclusion in formulations is particularly advantageous for patients undergoing treatment for pain management and neurological disorders. Magnesium sulfate has been shown to enhance the effectiveness of intrathecal injections by contributing to improved patient comfort and reducing the incidence of complications. As the market continues to expand, magnesium sulfate is likely to remain an important component of these specialized injections.

By Region

The North American region dominates the buffered intrathecal electrolyte dextrose injection market, accounting for approximately 40% of the global market share. This dominance is attributed to the presence of advanced healthcare infrastructure, high rates of chronic pain disorders, and a significant number of surgical procedures requiring effective pain management solutions. The growing acceptance of intrathecal injections among healthcare providers and increased investments in research and development further bolster the region's market growth. The North American market is expected to maintain a robust CAGR of around 7% through the forecast period, driven by continuous advancements in treatment methodologies and medical technologies.

Europe follows closely as the second-largest market for buffered intrathecal electrolyte dextrose injections, capturing around 30% of the global share. The region benefits from a well-established healthcare system and a growing emphasis on pain management therapies. The increasing prevalence of neurological disorders and the rising geriatric population further fuel demand for specialized treatments within Europe. Additionally, government initiatives aimed at improving healthcare access and affordability contribute to the region's expanding market. As healthcare professionals increasingly adopt innovative therapies, the European market is poised for steady growth in the coming years.

Opportunities

The buffered intrathecal electrolyte dextrose injection market presents numerous opportunities for growth, particularly as healthcare systems increasingly prioritize effective pain management solutions. The rising incidence of chronic pain and neurological disorders creates a significant demand for specialized treatments, including intrathecal injections. Furthermore, advancements in medical technology and drug formulations provide avenues for innovation, allowing companies to develop more effective and targeted products. The ongoing trend towards outpatient treatments and minimally invasive procedures also offers promising prospects, as healthcare providers seek to enhance patient comfort and recovery times. Overall, these factors collectively contribute to a favorable environment for expanding market opportunities and increased product adoption.

In addition to growing demand, the buffered intrathecal electrolyte dextrose injection market also benefits from an increasing focus on research and development. Pharmaceutical companies are investing in innovative formulations and delivery systems to improve the efficacy and safety of intrathecal injections. Collaborations between healthcare practitioners and researchers can lead to the identification of new applications and enhanced clinical outcomes, creating a robust pipeline of potential products in the market. Moreover, the rising trend of personalized medicine and tailored therapeutic approaches aligns with the market's growth trajectory, as healthcare providers seek to optimize treatment efficacy for individual patients.

Threats

One of the notable threats facing the buffered intrathecal electrolyte dextrose injection market is the regulatory scrutiny associated with injectable products. Stringent regulations and approval processes can pose challenges for manufacturers, potentially delaying the launch of new products and innovations. The complexity of clinical trials and the necessity of demonstrating safety and efficacy add to the burden on companies looking to enter the market. Additionally, any adverse events associated with intrathecal injections can lead to increased regulatory oversight, further complicating the development and approval process. Therefore, stakeholders in this market must navigate a constantly evolving regulatory landscape to ensure compliance and maintain market presence.

Moreover, the buffered intrathecal electrolyte dextrose injection market may face competition from alternative treatment modalities, such as oral medications and other non-invasive pain management strategies. As healthcare providers explore various options for managing pain and neurological conditions, intrathecal injections may not always be the first choice. The increasing emphasis on personalized medicine also means that patients may prefer tailored therapies that do not involve invasive procedures. This competition poses a significant challenge for the growth of the buffered intrathecal injection market, requiring manufacturers to continuously innovate and adapt to changing patient preferences and clinical practices.

Competitor Outlook

• Hospira, Inc.
• Fresenius Kabi AG
• AbbVie Inc.
• Teva Pharmaceuticals Industries Ltd.
• Hikma Pharmaceuticals PLC
• Amgen Inc.
• Aceto Corporation
• Ethics Pharmaceuticals
• Baxter International Inc.
• Sandoz International GmbH
• Zydus Cadila
• Par Pharmaceutical Companies, Inc.
• Sun Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Haleon plc

The competitive landscape of the buffered intrathecal electrolyte dextrose injection market is characterized by the presence of several major players that continually strive to enhance their product offerings and market reach. These companies focus on research and development to innovate formulations that cater to the evolving needs of healthcare professionals and patients. Moreover, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies among these players, providing opportunities to expand their market footprints and bolster their competitive advantage. The increased emphasis on patient safety and efficacy of injectable products further drives competition in this market segment.

Hospira, Inc., a key player in the healthcare industry, is recognized for its extensive range of injectable medications, including buffered intrathecal electrolyte dextrose injections. The company is dedicated to maintaining high-quality standards and continuously invests in research and development to enhance its product offerings. Another significant competitor, Fresenius Kabi AG, is known for its commitment to developing high-quality injectable solutions, including electrolyte formulations. Their focus on patient-centric solutions has positioned them as a leader in the intravenous and parenteral nutrition markets.

AbbVie Inc., a major pharmaceutical company, offers a variety of pain management solutions, including intrathecal injections, with a strong emphasis on innovative treatment options for chronic pain. Teva Pharmaceuticals Industries Ltd. also plays a crucial role in the market, leveraging its broad portfolio of generic and specialty pharmaceuticals to meet the demands of healthcare providers. These companies, along with others like Hikma Pharmaceuticals PLC and Amgen Inc., actively contribute to the growth and evolution of the buffered intrathecal electrolyte dextrose injection market through continuous innovation and a focus on improving patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Haleon plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Zydus Cadila
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hospira, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Aceto Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fresenius Kabi AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Ethics Pharmaceuticals
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Baxter International Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals PLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Sandoz International GmbH
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Mallinckrodt Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Par Pharmaceutical Companies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceuticals Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Buffered Intrathecal Electrolyte Dextrose Injection Sales Market, By Application
    • 6.1.1 Pain Management
    • 6.1.2 Neurology
    • 6.1.3 Oncology
    • 6.1.4 Anesthesia
    • 6.1.5 Others
  • 6.2 Buffered Intrathecal Electrolyte Dextrose Injection Sales Market, By Product Type
    • 6.2.1 Sodium Chloride Solution
    • 6.2.2 Ringer's Solution
    • 6.2.3 Normal Saline Solution
    • 6.2.4 Sterile Water
    • 6.2.5 Lactated Ringer's Solution
  • 6.3 Buffered Intrathecal Electrolyte Dextrose Injection Sales Market, By Ingredient Type
    • 6.3.1 Sodium Chloride
    • 6.3.2 Dextrose
    • 6.3.3 Calcium Chloride
    • 6.3.4 Potassium Chloride
    • 6.3.5 Magnesium Sulfate
  • 6.4 Buffered Intrathecal Electrolyte Dextrose Injection Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Buffered Intrathecal Electrolyte Dextrose Injection Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Buffered Intrathecal Electrolyte Dextrose Injection Sales market is categorized based on

By Product Type

• Sodium Chloride Solution
• Ringer's Solution
• Normal Saline Solution
• Sterile Water
• Lactated Ringer's Solution

By Application

• Pain Management
• Neurology
• Oncology
• Anesthesia
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Online Pharmacies
• Others

By Ingredient Type

• Sodium Chloride
• Dextrose
• Calcium Chloride
• Potassium Chloride
• Magnesium Sulfate

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hospira, Inc.
• Fresenius Kabi AG
• AbbVie Inc.
• Teva Pharmaceuticals Industries Ltd.
• Hikma Pharmaceuticals PLC
• Amgen Inc.
• Aceto Corporation
• Ethics Pharmaceuticals
• Baxter International Inc.
• Sandoz International GmbH
• Zydus Cadila
• Par Pharmaceutical Companies, Inc.
• Sun Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Haleon plc